

1 **Characterization of Blood Group Variants in an Omani Population by Comparison of Whole**  
2 **Genome Sequencing and Serology**

5 **Short Title:** Blood Group Variation in Oman

7 Paige E. Haffener<sup>1</sup>, Arwa Z. Al-Riyami<sup>2\*</sup>, Shoaib Al-Zadjali<sup>3</sup>, Mohammed Al-Rawahi<sup>4</sup>, Saif Al  
8 Hosni<sup>2</sup>, Ali Al Marhoobi<sup>4</sup>, Ammar Al Sheriyani<sup>5</sup>, and Ellen M. Leffler<sup>1\*</sup>

10 <sup>1</sup> Department of Human Genetics, The University of Utah School of Medicine, Salt Lake City,  
11 UT, USA

12 <sup>2</sup> Department of Hematology, Sultan Qaboos University Hospital, University Medical City,  
13 Muscat, Oman

14 <sup>3</sup> Sultan Qaboos Comprehensive Cancer Center, University Medical City, Muscat, Oman

15 <sup>4</sup> Department of Hematology, College of Medicine and Health Sciences, Sultan Qaboos  
16 University, Muscat, Oman

17 <sup>5</sup> Royal Oman Police Hospital, Muscat, Oman

18 \*Corresponding authors:

20 Ellen M. Leffler 15 N. 2030 E. Salt Lake City, UT 84112, [leffler@genetics.utah.edu](mailto:leffler@genetics.utah.edu), +1  
21 801-581-4422

22 Arwa Z. Al-Riyami PO Box: 35, Alkoudh.123 Sultanate of Oman, [arwa@squ.edu.om](mailto:arwa@squ.edu.om),  
23 [\(+968\) 2414 4915](tel:+96824144915)

25 **Word Counts:**

26 Text: 3,947

27 Abstract: 230

28 Figures and Tables: 7

29 References: 60

33 **Category:** Transfusion Medicine OR Red Cells, Iron, and Erythropoiesis

36 **Data Sharing Statement**

37 Aligned, whole genome sequencing files (BAM) and variant calls (VCF) are available at dbGap  
38 under accession number XXXXXX.

47 **Key Points**

48 • Utilizing whole genome sequencing to infer blood types in Omanis demonstrates high  
49 sensitivity for most blood groups  
50 • Population history influences blood group variation, necessitating population-specific  
51 genotype panels

52  
53 **Abstract**

54 Although blood group variation was first described over a century ago, our understanding of the  
55 genetic variation affecting antigenic expression on the red blood cell surface in many populations  
56 is lacking. This deficit limits the ability to accurately type patients, especially as serological testing  
57 is not available for all described blood groups, and targeted genotyping panels may lack rare or  
58 population-specific variants. Here, we perform serological assays across 24 antigens and whole  
59 genome sequencing on 100 Omanis, a population underrepresented in genomic databases. We  
60 inferred blood group phenotypes using the most commonly typed genetic variants. The comparison  
61 of serological to inferred phenotypes resulted in an average concordance of 96.9%. Among the 22  
62 discordances, we identify seven known variants in four blood groups that, to our knowledge, have  
63 not been previously reported in Omanis. Incorporating these variants for phenotype inference,  
64 concordance increases to 98.8%. Additionally, we describe five candidate variants in the Lewis,  
65 Lutheran, MNS, and P1 blood groups that may affect antigenic expression, although further  
66 functional confirmation is required. Notably, we identify several blood group alleles most common  
67 in African populations, likely introduced to Oman by gene flow over the last thousand years. These  
68 findings highlight the need to evaluate individual populations and their population history when  
69 considering variants to include in genotype panels for blood group typing. This research will  
70 inform future work in blood banks and transfusion services.

71

72 **Introduction**

73 In the 124 years since the discovery of the ABO blood group system, 45 different blood  
74 groups have been described in humans along with 50 associated blood group genes<sup>1</sup>. Despite  
75 extensive knowledge of these various blood group systems, most have been described via case  
76 studies, and recent population genomic analyses suggest there is much left to be discovered. For  
77 instance, a study of genomic variation in African, European, South Asian, East Asian, and  
78 American populations from the 1000 Genomes project<sup>2</sup> identified 1,241 nonsynonymous (NS)  
79 variants within 43 blood group genes, and reported that 1,000 of the NS variants (81%) were not

80 known blood group polymorphisms, yet 357 were extracellular and thus potentially antigenic<sup>3</sup>.  
81 Another study of the same dataset identified only 120 of 604 known blood group variants<sup>4</sup>, with  
82 36 of these found in at least one continental region where they had not previously been described<sup>4</sup>.  
83 This suggests that many known variants affecting blood group variation are rare, and that we still  
84 lack a complete understanding of the distribution of blood group alleles in many populations<sup>4</sup>.

85 For example, a recent study from Oman demonstrated that rare, undescribed variants likely  
86 affect antigenic expression in multiple blood groups<sup>5</sup>. In this study, targeted genotyping and  
87 serological assays were compared for 19 different antigens belonging to six blood group systems.  
88 Although overall concordance was high (>95%), Fy<sup>b</sup> was an exception (concordance 87%), and  
89 only 3 antigens had 100% concordance<sup>5</sup>. Discordances were likely due to the effect of genetic  
90 variants that were absent from the genotyping assay. While the prevalence of common blood group  
91 antigens or blood group alleles have been documented across much of the Arabian Peninsula<sup>6,7,8-</sup>  
92 <sup>11,12</sup>, no comparison of sequencing data and serology has been conducted to identify additional  
93 variants affecting antigenic expression in this region.

94 Targeted genotyping is increasingly being investigated as an alternative or complement to  
95 serology for blood group phenotyping<sup>13</sup>. Benefits of genotyping include improving red cell  
96 matching for multi-transfused patients, those at an increased risk of alloimmunization, such as  
97 patients with sickle cell disease, and those with autoantibodies. The addition of a genotyping  
98 strategy is of interest in Oman where hemoglobinopathies and risk of alloimmunization are  
99 common in the population<sup>14-16</sup>. However, a more complete picture of rare and population-specific  
100 variants affecting antigenic expression is necessary. Whole genome sequencing provides a  
101 comprehensive view of blood group loci, including indels and copy number variation, particularly  
102 at more complex loci such as those that determine the RH and MNS blood groups<sup>17,18</sup>.

103 Here, we compare antigen typing inferred by whole genome sequencing to antigen  
104 expression determined by serology to identify variants contributing to blood group variation in the  
105 Omani population. We identified seven variants that have previously not been described in  
106 Omanis. Additionally, we identified five candidate variants that may be affecting antigen  
107 expression in the Lewis, Lutheran, MNS and P1 blood groups by altering erythrocyte-specific  
108 transcription factor binding sites, or by altering the coding regions near alleles encoding the blood  
109 group antigens. These findings should be considered when selecting red cell genotyping platforms  
110 for blood banks and transfusion services in Oman and nearby regions.

111

112 **Methods**

113 Sample Collection

114 A description of the samples used in this analysis, including DNA extraction and shipping  
115 conditions, has been previously published<sup>19</sup>. Briefly, 100 healthy male and female Omani blood  
116 donors between the ages of 18 and 60 years attending the Sultan Qaboos University Hospital  
117 (SQUH) blood bank were randomly selected and consented for enrollment in the study. The  
118 Medical Research Ethics committee at the College of Medicine and Health Sciences, the Sultan  
119 Qaboos University approved this study (MREC #2034, 2019).

120 Blood Bank Methods

121 Red blood cell phenotyping was performed within 24 hours of collection at SQUH Blood  
122 bank using BioRad<sup>©</sup> antisera on freshly drawn samples per the manufacturer instructions  
123 (BioRad<sup>©</sup>, Cressier Switzerland) and as previously published<sup>12</sup>. The following blood systems and  
124 antigens were tested: ABO (A,B antigens), Rh (C,c,E,e antigens), Kell (K, k, Kp<sup>a</sup>, Kp<sup>b</sup> antigens),  
125 Kidd (Jk<sup>a</sup>, Jk<sup>b</sup> antigens), Duffy (Fy<sup>a</sup>,Fy<sup>b</sup> antigens), Lewis (Le<sup>a</sup>,Le<sup>b</sup> antigens), Lutheran (Lu<sup>a</sup>,Lu<sup>b</sup>  
126 antigens), and MNS (M,N,S,s antigens). A clear red cell button at the bottom of the phenotyping  
127 well was defined as a negative reaction for all antigens (grade 0). Rh D reactions of 0 or 1 are  
128 further tested for weak D. Reactions positive for weak D are reported as Rh D positive and  
129 reactions negative for weak D testing are reported as Rh D negative as per manufacturer  
130 instructions. Other reaction patterns were defined as positive and were graded (1-4) for each  
131 antigen phenotyped. We included known positive and negative samples as internal controls for  
132 each antigen.

133

134 Genome Sequencing, Alignment and Variant Calling

135 As previously described<sup>19</sup>, short read (150bp paired-end) whole genome sequencing was  
136 performed to an average coverage of 16X at the Huntsman Cancer Institute High-Throughput  
137 Genomics Shared Resource at the University of Utah. The sequence reads were aligned to GRCh38  
138 with BWA-MEM<sup>20</sup> and variants were called following the GATK best practices protocol<sup>21,22</sup>.  
139 Haplotype phasing was done using Eagle v2<sup>23</sup> to produce a haplotype variant call file.

140

141

142 Inferring Blood Group Phenotypes

143 *ABO, RHCE, Kell, Kidd, Duffy, Lewis, Lutheran, MNS, and P1 Inference with SNVs*

144 Using the databases available from ISBT<sup>1</sup> and BloodAntigens.com<sup>13</sup>, we curated a list of  
145 variants for inferring blood group phenotypes from SNV genotypes (Table 1).

146

147 *RHD and RHCE Copy Number Inference*

148 RHD phenotypes were inferred using a copy number analysis<sup>13</sup>. Using aligned reads  
149 filtered for a MAPQ > 20, coverage across the *RHD* locus (1:25272393-25330445) and *RHCE*  
150 locus (1:25360659-25430193) was calculated using SAMtools<sup>24</sup>. Using the equation described by  
151 Lane et al. 2018<sup>13</sup>, a ratio of *RHD* to *RHCE* coverage between 0-0.5 was classified as null, 0.6-1.5  
152 as hemizygous, and 1.6-2.5 as homozygous. *RHCE* C/c antigen phenotypes were also inferred  
153 using a copy number analysis suggested by Lane et al. <sup>13</sup>, comparing coverage of *RHCE* exon 2 to  
154 the entire *RHCE* locus. A ratio of coverage greater than or equal to 1.5 was inferred as C-c+, 0.5-  
155 1.4 as C+c+, and less than 0.5 as C+c-.

156

157 *MNS Copy Number Inference*

158 To identify copy number variation, we inferred the underlying copy number state from  
159 observed coverage at sites with high mappability in 1600bp windows across the *GYPA*, *GYPB* and  
160 *GYPE* loci using a Hidden Markov Model as previously described<sup>19,25</sup>.

161

162 *Concordance calculations*

163 We calculated two concordances in this analysis, considering the phenotype determined by  
164 serology as truth. The average concordance per blood group is defined as the overall percent of all  
165 correctly inferred phenotypes from genotype data for that blood group. For instance, for the Kidd  
166 blood group, this would be calculated as follows:

$$\frac{(\# \text{ Correctly Inferred as } Jk(a+b-), Jk(a+b+), \text{ and } Jk(a-b+) \text{ by Genotype})}{\text{Total # of individuals } (n = 100)} \times 100$$

167  
168 = Average Concordance

169 The antigen concordance is calculated per antigen and is defined as the percent of individuals with  
170 individual antigen expression correctly predicted by genotype inferences over the total number of

171 individuals. Using the Kidd blood group as an example, antigen concordance for the Jk(a) antigen  
172 would be calculated as follows:

173 
$$\frac{(\# \text{Correctly Inferred as } Jk(a+) \text{ and } Jk(a-))}{\text{Total # of individuals } (n = 100)} \times 100 = \text{Antigen Concordance for } Jk(a)$$

174

## 175 **Results**

176 In 100 Omani blood donors, we compared blood group phenotypes determined by serology  
177 (Table S1) and by inference from genetic variants called from whole genome sequencing data for  
178 a commonly used serology panel including ABO, Rh, Kell, Kidd, Duffy, Lewis, Lutheran, P1, and  
179 MNS (Table 1). Using the most common variants underlying the 24 antigens tested, we evaluated  
180 the concordance for each blood group system as well as for each antigen (Table 1). Across all  
181 blood group systems, the average concordance was 96.9% (Table 1). Two blood group systems  
182 had a phenotype-genotype concordance of 100% (Kell and Kidd). The remaining seven blood  
183 groups had a concordance greater than 95% with the exception of the MNS and RHCE C/c blood  
184 group systems which had concordances of 91%.

185 We identified a total of 22 discordant samples (Table S2). Among these, we identified  
186 seven known variants in eleven samples affecting antigen expression in the Rh, Duffy, Lewis, and  
187 MNS blood groups that were previously undescribed in the Omani population (Table 2). We also  
188 identified a putatively novel variant in the Lewis blood group as well as three variants in  
189 transcription factor binding sites specific to erythrocyte expression or erythropoiesis that could be  
190 altering antigen expression in the Lutheran and P1 blood groups (Table 3). Additionally, we  
191 identified a structural variant in the glycophorin gene region that may alter S antigen expression  
192 of the MNS blood group (Table 3). There are eight discordances without a candidate novel variant  
193 that remain unresolved, all of which are in the Rh and MNS blood groups. We discuss the  
194 discordances and the identified variants for each blood group in detail below.

195

### 196 ABO Blood Group

197 The AB and O antigens are encoded by the *ABO* gene on chromosome 9. Using rs8176747  
198 (Gly267Ala) and rs8176746 (Leu265Met) to infer the A and B antigens and rs8176719  
199 (Thr87AspfsTer107) to infer the O antigen resulted in a concordance of 98%. Because  
200 Thr87AspfsTer107 is most commonly found on a haplotype that expresses the A antigen<sup>26</sup>, 13

201 individuals heterozygous for all three SNVs were inferred as blood type B. However, the variants  
202 are not in complete linkage disequilibrium ( $D' = 0.8$ ) and one was found to express A by serology.  
203 The variants are too far apart for physical phasing, but this sample was imputed as carrying  
204 87AspfsTer107 on the same haplotype as the alleles encoding Ala and Met, consistent with the A  
205 blood type. The other discordant sample was called as homozygous for Thr87AspfsTer107 and  
206 thereby inferred as O blood type but expressed the B antigen via serology. Further investigation  
207 revealed that this individual had one read with the insertion. Sanger sequencing confirmed that this  
208 individual was in fact heterozygous for Thr87AspfsTer107, resolving this discordance.

209

210 Rh Blood Group

211 For the Rh blood group, we typed the D, C, c, E, and e antigens encoded by the adjacent  
212 *RHD* and *RHCE* genes. The presence of the *RHD* gene on chromosome 1 results in the expression  
213 of D antigen whereas homozygosity for a complete *RHD* gene deletion is the most common cause  
214 of the Rh D negative phenotype<sup>27</sup>. Serology and genotype inference were discordant for the D  
215 antigen in one individual. This sample was inferred as D+ by sequence data, supported by  
216 numerous reads mapping to the *RHD* gene but serologically, the D antigen was not detected. This  
217 individual was found to carry the *RHD* pseudogene allele (*RHD*\* $\psi$ ) that consists of a 37bp  
218 duplication in exon 4, which introduces a premature stop codon resulting in early truncation of the  
219 *RHD* gene<sup>28</sup>. The allele frequency (AF) of *RHD*\* $\psi$  in the Omanis is similar to the AF in  
220 African/African American population in gnomADv4.0<sup>29</sup> (Figure 1), with AFs of 0.0376 and  
221 0.0389, respectively. This is higher than the gnomADv4.0 Middle Eastern population  
222 (AF=0.0022), indicating heterogeneity across the Middle East, likely due to variation in African  
223 ancestry<sup>19</sup>.

224 The E and e antigens, determined by alternative alleles at rs609320 (Ala226Pro), had 99%  
225 concordance. The discordant sample, inferred as E-e+ but serologically reported as E+e+, was  
226 found to carry an allele known to cause weak E expression, rs141398055 (Arg201Thr)<sup>30</sup>.  
227 Arg201Thr has the highest allele frequency in Middle Eastern populations (AF = 0.0036) in  
228 gnomADv4.0 and a frequency of 0.015 in the Omanis (Figure 1, Table 2).

229 The C antigen results from the presence of *RHD* exon 2 sequence in the paralogous location  
230 in *RHCE* (likely due to gene conversion), which can be detected as misalignment of reads to *RHD*  
231 exon 2. We initially used the approach implemented by Lane et al.<sup>13</sup> comparing *RHCE* exon 2

232 coverage to the coverage of the *RHCE* locus. This resulted in a concordance of 91%. However,  
233 since the reads should be misaligning to *RHD* exon 2, we then compared the coverage across exon  
234 2 of both genes in individuals that were hemizygous or homozygous for *RHD*. To account for  
235 hemizygosity, we adjusted the coverage range to > 0.67 for C-c+, 0.1-0.66 for C+c+, and < 0.1 for  
236 C+c-. Using this approach, the C and c antigens had 99% concordance. The discordant sample was  
237 inferred as C-c+ but serologically reported as C+c+ (Table S2) and remains unresolved as they are  
238 D negative so we could not apply this second approach.

239

#### 240 Duffy Blood Group

241 The genotype-phenotype concordance and resolving variants for the Duffy blood group in  
242 this dataset have been previously published in an analysis of genetic ancestry and positive selection  
243 at the Duffy blood group locus, *ACKR1*<sup>19</sup>. Briefly, inference of Fy<sup>a</sup> and Fy<sup>b</sup> antigen expression  
244 using rs12075 (Gly42Asp) and rs2814778 for the erythrocyte silent (ES) allele, Fy<sup>ES</sup>, resulted in a  
245 concordance of 96%. We found three discordant individuals genetically inferred as Fy(a-b+) but  
246 serologically reported as Fy(a-b-) to carry the Duffy X allele, Fy<sup>X</sup> (rs34599082 Arg89Cys), that  
247 results in weak Fy<sup>b</sup> expression and had previously not been described in Oman<sup>31</sup>. The fourth  
248 discordant individual was also genetically inferred as Fy(a-b+) and serologically reported as Fy(a-  
249 b-), but they did not carry the Fy<sup>X</sup> allele. Instead, we identified a two base pair frameshift resulting  
250 in early protein termination (rs773692057 Ser62fs) carried by this individual, together with the  
251 Fy<sup>ES</sup> allele causing the Duffy negative phenotype. The frameshift allele is rare but present in  
252 additional individuals from Oman and other populations in the Arabian Peninsula<sup>19</sup>.

253

#### 254 Lewis Blood Group

255 Two loci must be considered when inferring phenotypes of the Lewis blood group. The  
256 secretor, Le(a-b+), and non-secretor, Le(a+b-), phenotypes are most commonly determined by a  
257 nonsense mutation (rs601338 Trp154Ter) in *FUT2* on chromosome 19<sup>32</sup> whereas the null  
258 phenotype, Le(a-b-), is caused by a variety of different alleles in *FUT3* that encode nonfunctional  
259 transferases, regardless of *FUT2* genotype<sup>33</sup>. We inferred the secretor phenotype using Trp154Ter  
260 in *FUT2* and the null phenotype using three different SNVs in *FUT3* that have been associated  
261 with Le(a-b-) in an Iranian population (rs28362459 Leu20Arg, rs812936 Arg68Trp, and rs778986  
262 Met105Thr)<sup>33</sup>. This resulted in a concordance of 96%. When expanding to consider additional

263 SNVs known to cause the null phenotype, we found that thirteen Omani individuals carried  
264 rs3894326 (Ile356Lys), a SNV commonly used for genotyping *FUT3* in European, South Asian  
265 and East Asian populations<sup>34,35</sup> (Figure 1) leading to a revised concordance of 99%. The remaining  
266 discordant sample was inferred as Le(a-b+), but the serology reported them as Le(a+b+), a rare  
267 phenotype indicating a functional *FUT3* allele but a weak secretor allele at *FUT2*. This individual  
268 carried a unique missense variant, rs373779096 (Ala335Thr), that is very rare in gnomadv4.0 but  
269 primarily found in individuals of African/African American or admixed American ancestry (AF =  
270 0.00037 and 0.00025 respectively) and in a single Middle Eastern individual (AF = 0.00017).  
271 Ala335Thr is located in the same exon as two other known weak secretor alleles (rs1047781  
272 Ile140Phe and rs532253708 Met99Leu) that reduce enzymatic activity of  
273 alpha(1,2)fucosyltransferase<sup>36-38</sup>, and therefore may represent a new weak secretor allele, though  
274 further confirmation is needed.

275

276 Lutheran Blood Group

277 The Lutheran blood group is encoded by the *BCAM* locus on chromosome 19. Using  
278 rs28399653 (Arg77His) to infer expression of Lu<sup>a</sup> and Lu<sup>b</sup> antigens, there was 99% concordance.  
279 The discordant sample was inferred as Lu(a-b+) by genotype but serologically reported as Lu(a-  
280 b-). The presence of Lu(a-b-) is consistent with the frequency observed in the previous study in  
281 Oman<sup>12</sup>, and suggests a higher frequency than elsewhere<sup>39-45</sup>. The Lu(a-b-) phenotype can either  
282 be due to homozygosity for loss of function alleles or expression of the *BCAM* gene below the  
283 level of detection by serology. The latter, referred to as In(Lu), is more common and has been  
284 attributed to heterozygous mutations affecting the transcription factor *EKLF*<sup>44</sup>. We looked for  
285 additional variants within the *BCAM* locus, in *EKLF*, and seven other erythroid transcription  
286 factors using the UCSC Genome Browser and JASPAR transcription factors tract<sup>44,46-48</sup>. We did  
287 not identify any loss-of-function alleles carried by this individual in *BCAM* or in *EKLF*. However,  
288 we did identify two adjacent SNVs falling in a GATA1 binding site for *SPII* that are unique to  
289 this individual and thus a candidate for a new allele encoding a In(Lu) phenotype (rs533045163  
290 and rs184739796). Neither SNV are reported in Middle Eastern individuals from the gnomADv4.0  
291 database. Although rare, they are most common to African/African American individuals (AF =  
292 0.006 for both SNVs).

293

294 MNS Blood Group

295 The MNS blood group consists of 48 antigens encoded by three glycophorin genes on  
296 chromosome 4: *GYPA*, *GYPB*, and *GYPE*. For this analysis, we only analyzed the M, N, S, and s  
297 antigens. We inferred phenotypes using both SNVs and copy number calling as structural variants  
298 have been found to affect the glycophorin loci<sup>1,25</sup>. Expression of the M and N antigens can be  
299 inferred by three SNVs in *GYPA*: rs7682260 (Leu20Ser), and rs7687256 and rs7658293  
300 (Glu24Gly)<sup>49</sup>. The resulting concordance was 94% (Figure 2A). Five of the six discordant samples  
301 were inferred as M-N+ whereas the remaining sample was M+N-. All six were reported as  
302 expressing both antigens (M+N+) by serology. It is likely the discordances are caused by difficulty  
303 aligning to this region due to the presence of the N antigen sequence in the reference at *GYPA* and  
304 *GYPB* and the M antigen sequence present in the reference at *GYPE*<sup>13</sup>. Additionally, we did not  
305 identify any structural variants that could be causing these discordances.

306 The S and s antigens, inferred using rs7683365 (Thr48Met) in *GYPB*, had a concordance  
307 of 97% (Figure 2B). One discordant sample was inferred as S+s- but serologically found to be S-  
308 s-. We identified SNVs at multiple sites in *GYPB*, consistent with the Henshaw variant  
309 GYP.He(P2), a common cause of the S-s-U+<sup>var</sup> phenotype in individuals with African ancestry<sup>50</sup>  
310 (Figure 1). In addition to affecting 3 amino acids (Leu20Trp, Thr23Ser, Glu24Gly), the  
311 GYP.He(P2) variant includes another SNV on the same haplotype that alters a donor splice site in  
312 intron 5 (270+5 G>T, rs139511876) causing exon 5 to be skipped post-transcriptionally<sup>50</sup>. Copy  
313 number calling also revealed the presence of a *GYPB* gene deletion in this sample (Figure 3). Thus,  
314 the combination of GYP.He(P2) and the *GYPB* deletion is consistent with the S-s- phenotype.

315 The second discordant sample, inferred as S+s+ but serologically found to be S+s-, was  
316 inferred to carry the Dantu structural variant (previously identified in Haffener et al. 2024<sup>19</sup>). The  
317 Dantu allele has been associated with protection from severe *Plasmodium falciparum* malaria and  
318 is most common in East African populations<sup>25</sup>. However, the Dantu allele is thought to express s  
319 antigens<sup>51</sup>, so it is unclear if Dantu alone resolves this discordance. The remaining discordant  
320 sample was inferred as S+s- but serologically found to express both antigens (S+s+). This sample  
321 does not carry any known or novel missense, nonsense, or structural variants that we could identify.

322

323

324

325 P1 Blood Group

326 We inferred the P<sub>1</sub> and P<sub>2</sub> phenotypes of the P1 blood group using four intronic variants in  
327 *A4GALT* on chromosome 22 reported to be associated with P1 antigen expression: rs66781836,  
328 rs5751348, rs8138197, and rs2143918<sup>52</sup>, although the causal variant remains unknown<sup>53</sup>.  
329 Phenotypes inferred with rs66781836 had the lowest accuracy with 97% concordance. The other  
330 three almost always occurred together and had a concordance of 99% suggesting rs66781836 is  
331 less likely to be the causal variant affecting P<sub>1</sub> antigen expression, consistent with previous  
332 results<sup>54,55</sup>. The discordant sample, inferred as P<sub>1</sub>, was heterozygous for all three SNVs despite the  
333 serology reporting them as P<sub>2</sub>. Given that one of the three most likely causal variants, rs5751348,  
334 falls within an intronic transcription factor binding site<sup>55</sup>, we investigated other transcription factor  
335 binding sites within the *A4GALT* locus. We identified one potentially causal variant that falls  
336 within a STAT1 transcription factor binding site. This variant at position 22:42,721,266 is absent  
337 from gnomADv4.0 and dbSNP, suggesting it is extremely rare. However, two Omanis were found  
338 to be heterozygous: the discordant sample and a concordant sample homozygous for all three  
339 reference alleles serologically reported as P1.

340

341 **Discussion**

342 Here, we comprehensively document the alleles underlying common blood group antigens  
343 in an Omani population by comparison of whole genome sequencing to serology. We demonstrate  
344 high concordance for all commonly tested blood group antigens in routine transfusion practice and  
345 report several recognized alleles altering blood group antigen expression that have previously not  
346 been described in Omanis. Notably, we describe alleles resolving discordances in the Rh, Duffy,  
347 Lewis, and MNS blood group systems (Table 2) in three or more unrelated individuals, suggesting  
348 these alleles are relatively common in the Omani population. Thus, these alleles should be  
349 considered for inclusion in red cell genotyping methods used in blood banks in Oman.  
350 Additionally, although singletons in this dataset, GYP.He(P2) and the 2 base pair *ACKR1*  
351 frameshift (Ser62fs), identified in a previous study with these samples<sup>19</sup>, should also be included  
352 given their resulting null phenotypes. These two alleles were also observed in other Arabian  
353 Peninsula and greater Middle Eastern populations indicating they are likely present throughout the  
354 region, although singletons in this dataset (Figure 1)<sup>19</sup>. Inclusion of additional populations from

355 this region would provide a better understanding of how prevalent these alleles are and their  
356 relevance to red cell genotyping methods in other Arabian Peninsula populations.

357 While the overall blood group concordance was high and we were able to resolve  
358 discrepancies with this approach (revised overall concordance = 98.8%, Table 4), this analysis also  
359 revealed limitations to inferring MNS, ABO and Rh blood group phenotypes from whole genome  
360 sequencing data. The whole genome sequencing data had an average coverage of 16X and read  
361 length of 150 bp which we found led to mismapping in the glycophorin gene region and difficulty  
362 inferring M/N antigen expression as previously suggested<sup>13</sup>. An instance of the *ABO* O allele  
363 (Thr87AspfsTer107) being miscalled as a homozygote rather than a heterozygote also suggests a  
364 deeper coverage could improve blood group inferences using commonly typed SNVs. Lastly, the  
365 most unresolved discordances are in the MNS and Rh blood groups, likely given the complexity  
366 of these loci. Long-read sequencing or alignment to a pangenome, which can improve  
367 identification of structural variants<sup>56,57</sup>, may be necessary for reliable inference of these blood  
368 groups from DNA sequence.

369 Although discordant samples were not fully resolved in the MNS, Lewis, Lutheran, and P1  
370 blood groups, we identified putatively causal variants that warrant further investigation. The Dantu  
371 SV identified in one of the discordant MNS samples has previously been believed to express the  
372 s+ antigen<sup>51</sup>. However, we did not identify any other potential causal variants within *GYPB* exons  
373 or cis-regulatory element binding sites that could have caused the S+s- phenotype in this  
374 individual. Within the Lewis blood group, we identified a SNV that could result in the weak  
375 secretor phenotype. Presently, only two weak secretor alleles have been described (Ile140Phe and  
376 Met99Leu)<sup>36-38</sup> which reduce enzymatic activity and fall within the same exon of *FUT2* as the  
377 allele we identified, Ala335Thr. We also identified a candidate regulatory variant in a GATA1  
378 transcription factor binding site of the erythrocyte-specific transcription factor locus, *SPI1* that  
379 could cause the In(Lu) phenotype as a result of reduced transcription of *SPI1*<sup>58</sup>, akin to the  
380 associated SNVs in a GATA1 binding site of *EKLF*<sup>44</sup>. Similarly, a candidate causal allele that falls  
381 within a binding site for the erythrocyte-specific transcription factor STAT1 in the 5'UTR of  
382 *A4GALT* may result in the absence of P1 antigen expression.

383 In conclusion, our findings document the alleles underlying common blood group antigens  
384 in Omanis and highlight the importance of considering population history when evaluating variants  
385 for blood group genotyping panels. For instance, the *RHD*\*ψ indel, erythrocyte-specific null allele

386 in the Duffy blood group, and GYP.He(P2) alleles are most common to African populations. These  
387 alleles were found in multiple Omani blood donors from this dataset and their prevalence in the  
388 population is consistent with what is known about the shared genetic ancestry of the Omanis with  
389 East African populations<sup>19,59,60</sup>. Overall, this study emphasizes the necessity to increase population  
390 representation in genotype databases and indicates that whole genome sequencing paired with  
391 serology is a valuable approach for doing so in transfusion practice.

392

### 393 **Acknowledgments**

394 This work was supported by the Omani Ministry of Higher Education, Innovation and  
395 Research (formally known as the Research Council, grant number RC/RG-  
396 MED/HAEM/18/02) and by the United States National Institutes of Health (grant number  
397 R35 GM147709 to E.M.L.). The support and resources from the Center for High Performance  
398 Computing at the University of Utah are gratefully acknowledged. The computational  
399 resources used were partially funded by the NIH Shared Instrumentation Grant  
400 1S10OD021644-01A1. P.E.H. was supported by T32 GM007464 and T32 GM141848. Lastly,  
401 we thank all blood donors for participation in this study.

402

403

### 404 **Authorship Contributions**

405 Conceptualization – A.Z.A. and E.M.L.; Methodology – P.E.H., S.A., A.A.S., and E.M.L.;  
406 Validation – E.M.L.; Formal Analysis – P.E.H.; Investigation – P.E.H., M.A., and S.A.H.;  
407 Resources – A.Z.A., and S.A.; Writing – Original Draft, P.E.H., A.Z.A., and E.M.L.; Writing –  
408 Review & Editing, A.Z.A. and S.A.; Visualization – P.E.H.; Supervision – A.Z.A., S.A., A.A.M.,  
409 and E.M.L.; Project Administration – A.Z.A.; Funding Acquisition – A.Z.A. and E.M.L. All  
410 authors have read and approved this manuscript.

411

### 412 **Conflict of Interest Disclosures**

413 The authors declare no conflicts of interest.

414

415

## References

416

417

1. ISBT. Red Cell Immunogenetics and Blood Group Terminology. Accessed February, 2024. <https://www.isbtweb.org/isbt-working-parties/rcibgt.html>
2. Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. *Nature*. Oct 28 2010;467(7319):1061-73. doi:10.1038/nature09534
3. Moller M, Joud M, Storry JR, Olsson ML. Erythrogene: a database for in-depth analysis of the extensive variation in 36 blood group systems in the 1000 Genomes Project. *Blood Adv*. Dec 27 2016;1(3):240-249. doi:10.1182/bloodadvances.2016001867
4. Montemayor-Garcia C, Karagianni P, Stiles DA, et al. Genomic coordinates and continental distribution of 120 blood group variants reported by the 1000 Genomes Project. *Transfusion*. Nov 2018;58(11):2693-2704. doi:10.1111/trf.14953
5. Al-Riyami AZ, Al Hinai D, Al-Rawahi M, et al. Molecular blood group screening in Omani blood donors. *Vox Sang*. Mar 2022;117(3):424-430. doi:10.1111/vox.13204
6. Ameen R, Al Shemmary S, Harris S, Teramura G, Delaney M. Classification of major and minor blood group antigens in the Kuwaiti Arab population. *Transfusion and Apheresis Science*. 2020/08/01/ 2020;59(4):102748. doi:<https://doi.org/10.1016/j.transci.2020.102748>
7. El-Zawahri MM, Luqmani YA. Molecular genotyping and frequencies of A1, A2, B, O1 and O2 alleles of the ABO blood group system in a Kuwaiti population. *Int J Hematol*. Apr 2008;87(3):303-9. doi:10.1007/s12185-008-0036-0
8. Belali TM. Distribution of ABO and Rhesus Types in the Northern Asir Region in Saudi Arabia. *J Blood Med*. 2022;13:643-648. doi:10.2147/jbm.S383151
9. Bashwari LA, Al-Mulhim AA, Ahmad MS, Ahmed MA. Frequency of ABO blood groups in the Eastern region of Saudi Arabia. *Saudi Med J*. Nov 2001;22(11):1008-12.
10. Alzahrani M, Jawdat D, Alaskar A, Cereb N, Hajeer AH. ABO and Rh blood group genotypes in a cohort of Saudi stem cell donors. *International Journal of Immunogenetics*. 2018;45(2):63-64. doi:<https://doi.org/10.1111/jji.12354>
11. Owaideh AY, Naffaa NM, Alumran A, Alzahrani F. Phenotype Frequencies of Major Blood Group Systems (Rh, Kell, Kidd, Duffy, MNS, P, Lewis, and Lutheran) Among Blood Donors in the Eastern Region of Saudi Arabia. *J Blood Med*. 2020;11:59-65. doi:10.2147/JBM.S236834
12. Al-Riyami AZ, Al-Marhoobi A, Al-Hosni S, et al. Prevalence of Red Blood Cell Major Blood Group Antigens and Phenotypes among Omani Blood Donors. *Oman Med J*. Nov 2019;34(6):496-503. doi:10.5001/omj.2019.92
13. Lane WJ, Westhoff CM, Gleadall NS, et al. Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. *Lancet Haematol*. Jun 2018;5(6):e241-e251. doi:10.1016/S2352-3026(18)30053-X
14. Al-Riyami AZ, Al-Mahrooqi S, Al-Hinai S, Al-Hosni S, Al-Madhani A, Daar S. Transfusion therapy and alloimmunization in Thalassemia Intermedia: a 10 year experience at a tertiary care university hospital. *Transfus Apher Sci*. Aug 2014;51(1):42-6. doi:10.1016/j.transci.2014.04.009
15. Al-Riyami AZ, Al-Muqbali A, Al-Sudiri S, et al. Risks of red blood cell alloimmunization in transfusion-dependent beta-thalassemia in Oman: a 25-year experience of a university tertiary care reference center and a literature review. *Transfusion*. Apr 2018;58(4):871-878. doi:10.1111/trf.14508

461 16. Al-Riyami AZ, Daar S. Transfusion in Haemoglobinopathies: Review and  
462 recommendations for local blood banks and transfusion services in Oman. *Sultan Qaboos Univ*  
463 *Med J*. Feb 2018;18(1):e3-e12. doi:10.18295/squmj.2018.18.01.002

464 17. Liu Z, Liu M, Mercado T, Illoh O, Davey R. Extended blood group molecular typing and  
465 next-generation sequencing. *Transfus Med Rev*. Oct 2014;28(4):177-86.  
466 doi:10.1016/j.tmrv.2014.08.003

467 18. Lane WJ, Westhoff CM, Uy JM, et al. Comprehensive red blood cell and platelet antigen  
468 prediction from whole genome sequencing: proof of principle. *Transfusion*. Mar 2016;56(3):743-  
469 54. doi:10.1111/trf.13416

470 19. Haffener PE, Al-Riyami AZ, Al-Zadjali S, et al. Adaptive admixture at ACKR1 (the  
471 Duffy locus) may have shaped *Plasmodium vivax* prevalence in Oman. *bioRxiv*.  
472 2024:2024.03.06.583766. doi:10.1101/2024.03.06.583766

473 20. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.  
474 *arXiv:13033997*. 2013;doi:<https://doi.org/10.48550/arXiv.1303.3997>

475 21. Freed DN, Aldana R, Weber JA, Edwards JS. The Sentieon Genomics Tools - A fast and  
476 accurate solution to variant calling from next-generation sequence data. *bioRxiv*. May 12, 2017  
477 2017;doi:<https://doi.org/10.1101/115717>

478 22. Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence  
479 variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics*.  
480 2013;43(1110):11 10 1-11 10 33. doi:10.1002/0471250953.bi1110s43

481 23. Loh PR, Danecek P, Palamara PF, et al. Reference-based phasing using the Haplotype  
482 Reference Consortium panel. *Nat Genet*. Nov 2016;48(11):1443-1448. doi:10.1038/ng.3679

483 24. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and  
484 SAMtools. *Bioinformatics*. Aug 15 2009;25(16):2078-9. doi:10.1093/bioinformatics/btp352

485 25. Leffler EM, Band G, Busby GBJ, et al. Resistance to malaria through structural variation  
486 of red blood cell invasion receptors. *Science*. Jun 16  
487 2017;356(6343)doi:10.1126/science.aam6393

488 26. Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the  
489 histo-blood group ABO system. *Nature*. May 17 1990;345(6272):229-33. doi:10.1038/345229a0

490 27. Wagner FF, Flegel WA. RHD gene deletion occurred in the Rhesus box. *Blood*. Jun 15  
491 2000;95(12):3662-8.

492 28. Singleton BK, Green CA, Avent ND, et al. The presence of an RHD pseudogene  
493 containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative  
494 blood group phenotype. *Blood*. Jan 1 2000;95(1):12-8.

495 29. Chen S, Francioli LC, Goodrich JK, et al. A genome-wide mutational constraint map  
496 quantified from variation in 76,156 human genomes. *bioRxiv*. 2022:2022.03.20.485034.  
497 doi:10.1101/2022.03.20.485034

498 30. Bugert P, Scharberg EA, Geisen C, von Zabern I, Flegel WA. RhCE protein variants in  
499 Southwestern Germany detected by serologic routine testing. *Transfusion*. Sep 2009;49(9):1793-  
500 802. doi:10.1111/j.1537-2995.2009.02220.x

501 31. Tournamille C, Le Van Kim C, Gane P, et al. Arg89Cys substitution results in very low  
502 membrane expression of the Duffy antigen/receptor for chemokines in Fy(x) individuals. *Blood*.  
503 Sep 15 1998;92(6):2147-56.

504 32. Daniels G. The molecular genetics of blood group polymorphism. *Hum Genet*. Dec  
505 2009;126(6):729-42. doi:10.1007/s00439-009-0738-2

506 33. Farahmand M, Jalilvand S, Arashkia A, et al. Estimation of genetic variation in the  
507 Secretor and Lewis genes in Iranian hospitalized children. *Transfus Clin Biol*. Feb  
508 2021;28(1):11-15. doi:10.1016/j.tracli.2020.12.001

509 34. Hu D, Zhang D, Zheng S, Guo M, Lin X, Jiang Y. Association of Ulcerative Colitis with  
510 FUT2 and FUT3 Polymorphisms in Patients from Southeast China. *PLoS One*.  
511 2016;11(1):e0146557. doi:10.1371/journal.pone.0146557

512 35. Taylor-Cousar JL, Zariwala MA, Burch LH, et al. Histo-blood group gene  
513 polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease  
514 severity. *PLoS One*. 2009;4(1):e4270. doi:10.1371/journal.pone.0004270

515 36. Soejima M, Koda Y. Detection of the weak-secretor rs1047781 (385A>T) single  
516 nucleotide polymorphism using an unlabeled probe high-resolution melting-based method.  
517 *ELECTROPHORESIS*. 2021;42(12-13):1362-1365. doi:<https://doi.org/10.1002/elps.202000386>

518 37. Soejima M, Koda Y. Survey and characterization of nonfunctional alleles of FUT2 in a  
519 database. *Sci Rep*. Feb 4 2021;11(1):3186. doi:10.1038/s41598-021-82895-w

520 38. Henry S, Mollicone R, Fernandez P, Samuelsson B, Oriol R, Larson G. Molecular basis  
521 for erythrocyte Le(a+ b+) and salivary ABH partial-secretor phenotypes: expression of a FUT2  
522 secretor allele with an A-->T mutation at nucleotide 385 correlates with reduced alpha(1,2)  
523 fucosyltransferase activity. *Glycoconj J*. Dec 1996;13(6):985-93. doi:10.1007/bf01053194

524 39. Rowe GP, Gale SA, Daniels GL, Green CA, Tippett P. A study on Lu-null families in  
525 South Wales. *Ann Hum Genet*. Jul 1992;56(3):267-72. doi:10.1111/j.1469-1809.1992.tb01151.x

526 40. Darnborough J, Firth R, Biles CM, Goldsmith KL, Crawford MN. A "new" antibody anti-  
527 Lu-a-Lu-b and two further examples of the genotype Lu(a-b-). *Nature*. May 25 1963;198:796.  
528 doi:10.1038/198796a0

529 41. Brown F, Simpson S, Cornwall S, Moore BP, Oyen R, Marsh WL. The recessive Lu(a-b-)  
530 ) phenotype. A family study. *Vox Sang*. Mar 1974;26(3):259-64. doi:10.1111/j.1423-  
531 0410.1974.tb02694.x

532 42. Myhre B, Thompson M, Anson C, Fishkin B, Carter PK. A Further Example of the  
533 Recessive Lu(a-b-) Phenotype. *Vox Sanguinis*. 1975;29(1):66-68.  
534 doi:<https://doi.org/10.1111/j.1423-0410.1975.tb00478.x>

535 43. Karamatic Crew V, Mallinson G, Green C, et al. Different inactivating mutations in the  
536 LU genes of three individuals with the Lutheran-null phenotype. *Transfusion*. Mar  
537 2007;47(3):492-8. doi:10.1111/j.1537-2995.2006.01141.x

538 44. Singleton BK, Burton NM, Green C, Brady RL, Anstee DJ. Mutations in EKLF/KLF1  
539 form the molecular basis of the rare blood group In(Lu) phenotype. *Blood*. Sep 1  
540 2008;112(5):2081-8. doi:10.1182/blood-2008-03-145672

541 45. Singleton BK, Roxby DJ, Stirling JW, et al. A novel GATA1 mutation (Stop414Arg) in a  
542 family with the rare X-linked blood group Lu(a-b-) phenotype and mild macrothrombocytic  
543 thrombocytopenia. *Br J Haematol*. Apr 2013;161(1):139-42. doi:10.1111/bjh.12184

544 46. Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. *Genome*  
545 *Res*. Jun 2002;12(6):996-1006. doi:10.1101/gr.229102

546 47. Castro-Mondragon JA, Riudavets-Puig R, Rauluseviciute I, et al. JASPAR 2022: the 9th  
547 release of the open-access database of transcription factor binding profiles. *Nucleic Acids Res*.  
548 Jan 7 2022;50(D1):D165-D173. doi:10.1093/nar/gkab1113

549 48. Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, et al. JASPAR 2024: 20th  
550 anniversary of the open-access database of transcription factor binding profiles. *Nucleic Acids*  
551 *Res*. Jan 5 2024;52(D1):D174-D182. doi:10.1093/nar/gkad1059

552 49. Furst D, Tsamadou C, Neuchel C, Schrezenmeier H, Mytilineos J, Weinstock C. Next-  
553 Generation Sequencing Technologies in Blood Group Typing. *Transfus Med Hemother*. Feb  
554 2020;47(1):4-13. doi:10.1159/000504765

555 50. Storry JR, Reid ME, Fetters S, Huang CH. Mutations in GYPB exon 5 drive the S-s-  
556 U+(var) phenotype in persons of African descent: implications for transfusion. *Transfusion*. Dec  
557 2003;43(12):1738-47. doi:10.1046/j.0041-1132.2003.00585.x

558 51. Blumenfeld OO, Smith AJ, Moulds JJ. Membrane glycoporphins of Dantu blood group  
559 erythrocytes. *J Biol Chem*. Aug 25 1987;262(24):11864-70.

560 52. Lane WJ, Aguad M, Smeland-Wagman R, et al. A whole genome approach for  
561 discovering the genetic basis of blood group antigens: independent confirmation for P1 and  
562 Xg(a). *Transfusion*. Mar 2019;59(3):908-915. doi:10.1111/trf.15089

563 53. Stenfelt L, Hellberg A, Westman JS, Olsson ML. The P1PK blood group system:  
564 revisited and resolved. *Immunohematology*. Sep 2020;36(3):99-103.

565 54. Lai YJ, Wu WY, Yang CM, et al. A systematic study of single-nucleotide  
566 polymorphisms in the A4GALT gene suggests a molecular genetic basis for the P1/P2 blood  
567 groups. *Transfusion*. Dec 2014;54(12):3222-31. doi:10.1111/trf.12771

568 55. Westman JS, Stenfelt L, Vidovic K, et al. Allele-selective RUNX1 binding regulates P1  
569 blood group status by transcriptional control of A4GALT. *Blood*. Apr 5 2018;131(14):1611-  
570 1616. doi:10.1182/blood-2017-08-803080

571 56. Liao WW, Asri M, Ebler J, et al. A draft human pangenome reference. *Nature*. May  
572 2023;617(7960):312-324. doi:10.1038/s41586-023-05896-x

573 57. Miller DE, Sulovari A, Wang T, et al. Targeted long-read sequencing identifies missing  
574 disease-causing variation. *The American Journal of Human Genetics*. 2021/08/05/  
575 2021;108(8):1436-1449. doi:<https://doi.org/10.1016/j.ajhg.2021.06.006>

576 58. Ballas SK, Marcolina MJ, Crawford MN. In vitro storage and in vivo survival studies of  
577 red cells from persons with the In(Lu) gene. *Transfusion*. Sep 1992;32(7):607-11.  
578 doi:10.1046/j.1537-2995.1992.32792391031.x

579 59. Fernandes V, Brucato N, Ferreira JC, et al. Genome-Wide Characterization of Arabian  
580 Peninsula Populations: Shedding Light on the History of a Fundamental Bridge between  
581 Continents. *Mol Biol Evol*. Mar 1 2019;36(3):575-586. doi:10.1093/molbev/msz005

582 60. Ferreira JC, Alshamali F, Montinaro F, et al. Projecting Ancient Ancestry in Modern-Day  
583 Arabians and Iranians: A Key Role of the Past Exposed Arabo-Persian Gulf on Human  
584 Migrations. *Genome Biol Evol*. Sep 1 2021;13(9):doi:10.1093/gbe/evab194

585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597

598 **Tables**

599

600 **Table 1.** Blood group system and antigen concordances from the comparison of blood typing by  
601 serology and inference from the commonly typed genetic variants. Variant information and allele  
602 frequency in this dataset are shown in the last two columns.

Blood Group	Average Concordance <sup>†</sup>	Blood Group Antigens	Antigen Frequency (% positive)	Antigen Concordance*	Variant(s)	Allele Frequency
ABO	98%	A	24%	99%	rs8176747 (Gly267Ala) rs8176746 (Leu266Met) rs8176719 (Thr87Ter)	0.095
		B	17%	99%		0.095 0.21
RHD	99%	D	92%	99%	<i>RHD</i> Deletion	0.19
RHCE	91%	C	69%	92%	<i>RHCE</i> Exon 2 Deletion	0.46
		c	71%	100%		
		E	23%	99%		0.12
		e	97%	100%	rs609320 (Ala226Pro)	
		K	7%	100%	rs8176058 (Thr193Met)	0.035
Kell	100%	k	100%	100%		
		Kp(a)	2%	100%	rs8176059 (Arg281Trp)	0.01
		Kp(b)	100%	100%		
		Jk(a)	84%	100%	rs1058396 (Asp280Asn)	0.36
Kidd	100%	Jk(b)	56%	100%		
		Fy(a)	7%	100%	rs12075 (Gly42Asp) rs2814778 (-67 T>C)	0.955
Duffy	96%	Fy(b)	7%	96%		0.89
		Le(a)	15%	98%	rs601338 (Trp154Ter) rs28362459 (Leu20Arg) rs812936 (Arg68Trp) rs778986 (Met105Thr)	0.405
Lewis	96%	Le(b)	69%	98%		0.125 0.725 0.735
		Lu(a)	3%	100%		
Lutheran	99%	Lu(b)	93%	99%	rs28399653 (Arg77His)	0.015
		M	94%	95%		
MNS	91%	N	59%	99%	rs7682260 (Leu20Ser) rs7687256 + rs7658293 (Glu24Gly)	0.64 0.62
		S	63%	99%		
		s	81%	98%	rs7683365 (Thr48Met)	0.415
		P1	79%	99%		
					rs5751348 (-188+3010G>T) rs8138197 (-188+2252C>T) rs2143918 (-188+2783T>G)	0.41 0.425 0.425

603 <sup>†</sup>Average concordance is calculated as the overall percent of correctly inferred individuals (n = 100) predicted by  
604 genetic variants per blood group.

605 \*Antigen concordance is calculated as the percent of individuals with each antigen expression correctly predicted by  
606 the genetic variants.

607

608

609

610

611

612

613

614

615

616

617

618

619 **Table 2.** Summary of known variants resolving discrepancies between inferred phenotypes from  
 620 whole genome sequence data and phenotypes reported by serology in the Omani samples.

Blood Group	Phenotype by Serology	Inferred Phenotype	Resolving Variant	Allele Frequency	Number of Discrepancies
Rh	D-	D+	RHD* $\psi$ <sup>28</sup> rs748783394	0.0376	1
Rh	E+e+	E-e+	rs141398055 (Arg201Thr)	0.015	1
Duffy	Fy(a-b-)	Fy(a-b+)	Duffy X rs34599082 (Arg89Cys) <sup>19</sup>	0.015	3
Duffy	Fy(a-b-)	Fy(a-b+)	rs773692057 (Ser62fs) <sup>19</sup>	0.005	1
Lewis	Le(a-b-)	Le(a-b+)	rs3894326 (Ile356Lys)	0.065	2
Lewis	Le(a-b-)	Le(a+b-)	rs3894326 (Ile356Lys)	0.065	1
MNS	S-s-	S+s-	GYP.He(P2) <sup>50</sup> rs139511876; DEL1 <sup>25</sup>	0.01; 0.015	1

621  
 622  
 623  
 624

**Table 3.** Summary of putatively novel causal variants identified in the discordant Omani samples.

Blood Group	Phenotype by Serology	Inferred Phenotype	Candidate Variants	Variant Effect	Allele Frequency	Number of Discrepancies
Lewis	Le(a+b+)	Le(a-b+)	rs373779096	Amino acid change	0.005	1
Lutheran	In(Lu)	Lu(a-b+)	rs533045163 and rs184739796	GATA1 binding site	0.005 and 0.005	1
MNS	S+s-	S+s+	Dantu Structural variant	GYPA – GYPB copy number variation	0.005	1
P1	P2	P1	Chr22:42,721,266 (A4GALT, -289A>C)	STAT1 binding site	0.01	1

625  
 626  
 627  
 628  
 629

**Table 4.** Adjusted per blood group concordances when including variants that resolved discrepancies (Table 2) between inferred phenotypes from whole genome sequence data and phenotypes reported by serology in the Omani samples.

Blood Group	Average Concordance	Revised Concordance
ABO	98%	100%
RHD	99%	100%
RHCE	91%	99%
Kell	100%	100%
Kidd	100%	100%
Duffy	96%	100%
Lewis	96%	99%
Lutheran	99%	99%
MNS	91%	92%
P1	99%	99%

630  
 631  
 632  
 633  
 634  
 635  
 636  
 637  
 638  
 639  
 640  
 641  
 642  
 643  
 644  
 645

646 **Figures Legends**

647

648 **Figure 1.** Allele frequencies of known blood group variants newly described in the Omani  
649 population (OM) compared to frequencies reported for Middle Eastern (ME), African (AFR),  
650 South Asian (SAS), and European (EUR) populations in gnomAD v4.0.

651

652 **Figure 2.** Alluvial plots showing the discordances in the MNS blood group. The left side of the  
653 plots are phenotypes determined by serology, and the right side are the phenotypes inferred by  
654 whole genome sequence data. The colors correspond to phenotypes inferred by serology. A) 88%  
655 concordance for the M and N antigens. B) 97% concordance for the S and s antigens.

656


657 **Figure 3.** Copy number inference across the glycophorin genes based on read coverage. The x-  
658 axis corresponds to positions across the glycophorin gene region on chromosome 4. The vertical  
659 black bars indicate the genes from left to right: *GYPE*, *GYPB*, *GYPA*. The y-axis is labelled by  
660 each sample in the Omani dataset inferred as having a structural variant, except for HG02554  
661 which is a 1000 genomes sample known to carry the Dantu structural variant. The dotted  
662 horizontal gray lines separate the inference for each sample. The colors correspond to the  
663 number of gene copies with white regions indicating two copies (no copy number variation  
664 relative to the reference).

665

666 **Figures**


667

668 **Figure 1**




669

670 **Figure 2**  
671  
672



673  
674  
675  
676  
677  
678  
679  
680  
681

682 **Figure 3**



683